Contact Information

XORTX Pharma Corp.

4000, 421 7th Ave SW
Calgary, Alberta
T2P 4K9
Ph: 1-403-455-7727

Request Information



XORTX Therapeutic Inc. is a publically traded company on the Canadian Stock Exchange (CSE). The company has two phase II drug development programs focused on developing treatments for unmet medical need in Autosomal Dominant Polycystic Kidney disease (ADPKD) and Diabetic Nephropathy (DN).

ADPKD is a rare disease – “Orphan disease”, where aberrant purine metabolism and high serum uric acid may be accelerating the rate of disease progression. Uric acid has been demonstrated to be an independent risk factor for accelerated loss of filtering capacity of kidneys in this disease. Recent phase 2 pilot studies showed that uric acid lowering may prove to be the most viable approach currently under development for patients with ADPKD currently under development.

Diabetic Nephropathy (DN) is a progressive kidney disease with no therapeutic options currently approved.  In the US nearly 40% of the estimated 23,000,000 type 2 diabetes patients will have symptoms of DN. As is the case with ADPKD, recent Phase 2 clinical pilot studies in patients with diabetic nephropathy or chronic kidney disease, have demonstrated that uric acid management may be a leading opportunity to slow or stop the progression of the large unmet medical need. Our recently granted US patent and anticipated EU patent provide the right to exclude others from gaining marketing approval for drugs addressing this mechanism of action.

We also have two product programs in early development for metabolic syndrome and chronic liver disease.

XORTX Therapeutics Inc. controls issued patents and patent applications claiming US and Worldwide rights for all uric acid lowering agents for the treatment of hypertension, metabolic syndrome, diabetes, and diabetic nephropathy/kidney injury.

XORTX Therapeutics Inc. – 5 KEY STRENGTHS

  1. Strong Management Team– with experience in early drug development to market approval, tailored to developing Oxypurinol through Orphan & New Drug Application (NDA).
  2. Orphan Drugs = Lower development costs and faster time to market– orphan disease programs have a robust market for pharma partnering when successful phase 2 results available.
  3. Numerous phase II clinical trials transform our phase 2 programs from pioneering to reproducing results. – clinical data in ADPKD and DN strongly support developing drugs tailored treat progressive kidney disease by inhibiting this mechanism of disease progression.
  4. For our Orphan Disease Programs repositioning Oxypurinol – is an ideal fast track approach owing to the well established effectiveness and safety profile of this drug.
  5. Historical Precedent for a Robust Orphan Diseases Market – many companies or their programs are acquired once phase 2 clinical data in support of a therapeutic approach is Recent phase 2 clinical pilot study results suggest a high probability for translating this program into a near future phase 2 success.